Monte Rosa Therapeutics, Inc. SEC filings GLUE
Monte Rosa Therapeutics, Inc. has 401 filings in SEC EDGAR's recent list, going back to Sep 29, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Mar 17, 2026 | — |
| S-3ASR | Automatic shelf registration | Feb 11, 2026 | — |
| 424B5 | Prospectus supplement | Jan 9, 2026 | — |
| 424B5 | Prospectus supplement | Jan 7, 2026 | — |
| S-3 | Shelf registration | Mar 20, 2025 | — |
| S-8 | Employee stock plan registration | Mar 20, 2025 | — |
| 424B5 | Prospectus supplement | May 16, 2024 | — |
| 424B5 | Prospectus supplement | May 15, 2024 | — |
| S-8 | Employee stock plan registration | Mar 14, 2024 | — |
| 424B5 | Prospectus supplement | Oct 26, 2023 | — |
| S-8 | Employee stock plan registration | Mar 16, 2023 | — |
| S-3 | Shelf registration | Jul 1, 2022 | — |
| S-8 | Employee stock plan registration | Mar 29, 2022 | — |
| S-8 | Employee stock plan registration | Jun 25, 2021 | — |
| 424B4 | Prospectus | Jun 25, 2021 | — |
| S-1MEF | Filing | Jun 23, 2021 | — |
| S-1/A | Amended registration statement | Jun 21, 2021 | — |
| S-1/A | Amended registration statement | Jun 9, 2021 | — |
| S-1 | Registration statement | Jun 4, 2021 | — |
Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GLUE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1826457
- Former names
- Monte Rosa Therapeutics, Inc. (until Nov 5, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.